

## SUMMARY OF PRODUCTS CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

Levonorgestrel HTP 1,5 mg, tabletten

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 1.5 mg of levonorgestrel.

#### Excipient with known effect

Each tablet contains 154 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Tablet

Round, white to off-white, 8.00 mm diameter, uncoated flat tablets debossed '1.5' on one side and other side plain.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Emergency contraception within 72 hours of unprotected sexual intercourse or failure of a contraceptive method.

#### 4.2 Posology and method of administration

##### Posology

One tablet should be taken as soon as possible, preferably within 12 hours, and no later than 72 hours after unprotected intercourse (see section 5.1).

If vomiting occurs within three hours of taking the tablet, another tablet should be taken immediately.

Women who have used enzyme-inducing drugs during the last 4 weeks and need emergency contraception are recommended to use a non-hormonal EC, i.e. Cu-IUD or take a double dose of levonorgestrel (i.e. 2 tablets taken together) for those women unable or unwilling to use Cu-IUD (see section 4.5).

<Invented name> 1.5 mg can be used at any time during the menstrual cycle unless menstrual bleeding is overdue.

After using emergency contraception it is recommended to use a barrier method (e.g. condom, diaphragm or cap) until the next menstrual period starts. The use of <Invented name> 1.5 mg does not contraindicate the continuation of regular hormonal contraception.

*Paediatric population:*

There is no relevant use of <Invented name> for children of prepubertal age in the indication emergency contraception.

Method of administration

For oral use.

**4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

**4.4 Special warnings and precautions for use**

Emergency contraception is an **occasional** method. It should in no instance replace a regular contraceptive method.

Emergency contraception does not prevent a pregnancy in every instance. If there is uncertainty about the timing of the unprotected intercourse or if the woman has had unprotected intercourse more than 72 hours earlier in the same menstrual cycle, conception may have occurred. Treatment with levonorgestrel 1.5 mg following the second act of intercourse may therefore be ineffective in preventing pregnancy. If menstrual periods are delayed by more than 5 days or abnormal bleeding occurs at the expected date of menstrual periods or pregnancy is suspected for any other reason, pregnancy should be excluded.

**If pregnancy occurs after treatment with levonorgestrel 1.5 mg, the possibility of an ectopic pregnancy should be considered.** The absolute risk of ectopic pregnancy is likely to be low, as levonorgestrel 1.5 mg prevents ovulation and fertilisation. Ectopic pregnancy may continue, despite the occurrence of a uterine bleeding.

Therefore, levonorgestrel 1.5 mg is not recommended for patients who are at risk of ectopic pregnancy (previous history of salpingitis or of ectopic pregnancy).

Levonorgestrel 1.5 mg is not recommended in patients with severe hepatic dysfunction. Severe malabsorption syndromes, such as Crohn's disease, might impair the efficacy of levonorgestrel 1.5 mg.

After levonorgestrel 1.5 mg intake, menstrual periods are usually normal and occur at the expected date. They can sometimes occur earlier or later than expected by a few days. Women should be advised to make a medical appointment to initiate or adopt a method of regular contraception. If no withdrawal bleed occurs in the next pill-free period following the use of levonorgestrel 1.5 mg after regular hormonal contraception, pregnancy should be ruled out.

Repeated administration within a menstrual cycle is not advisable because of the possibility of disturbance of the cycle.

Limited and inconclusive data suggest that there may be reduced efficacy of levonorgestrel 1.5 mg with increasing body weight or body mass index (BMI) (see section 5.1). In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.

Levonorgestrel 1.5 mg is not as effective as a conventional regular method of contraception and is suitable only as an emergency measure. Women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.

Use of emergency contraception does not replace the necessary precautions against sexually transmitted diseases.

#### Excipient

This medicinal product contains lactose.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

The metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers, mainly CYP3A4 enzyme inducers. Concomitant administration of efavirenz has been found to reduce plasma levels of levonorgestrel (AUC) by around 50 %.

Drugs suspected of having similar capacity to reduce plasma levels of levonorgestrel include barbiturates (including primidone), phenytoin, carbamazepine, herbal medicines containing *Hypericum perforatum* (St. John's Wort), rifampicin, ritonavir, rifabutin and griseofulvin.

For women who have used enzyme-inducing drugs in the past 4 weeks and need emergency contraception, the use of non-hormonal emergency contraception (i.e. a Cu-IUD) should be considered. Taking a double dose of levonorgestrel (i.e. 3000 mcg within 72 hours after the unprotected intercourse) is an option for women who are unable or unwilling to use a Cu-IUD, although this specific combination (a double dose of levonorgestrel during concomitant use of an enzyme inducer) has not been studied.

Medicines containing levonorgestrel may increase the risk of cyclosporin toxicity due to possible inhibition of cyclosporin metabolism.

#### **4.6 Fertility, pregnancy and lactation**

##### Pregnancy

Levonorgestrel 1.5 mg should not be given to pregnant women. It will not interrupt a pregnancy. In the case of continued pregnancy, limited epidemiological data indicate no adverse effects on the foetus but there are no clinical data on the potential consequences if doses greater than 1.5 mg of levonorgestrel are taken (see section 5.3).

##### Breast-feeding

Levonorgestrel is secreted into breast milk. Potential exposure of an infant to levonorgestrel can be reduced if the breast-feeding woman takes the tablet immediately after feeding and avoids nursing at least 8 hours following levonorgestrel 1.5 mg administration.

##### Fertility

Levonorgestrel increases the possibility of cycle disturbances which can sometimes lead to earlier or later ovulation date resulting in modified fertility date. Although there are no fertility data in the long term, after treatment with levonorgestrel a rapid return to fertility is expected and therefore, regular contraception should be continued or initiated as soon as possible after levonorgestrel EC use.

#### **4.7 Effects on ability to drive and use machines**

No studies on the effect on the ability to drive and use machines have been performed.

#### 4.8 Undesirable effects

The most commonly reported undesirable effect was nausea.

| System Organ Class<br>MedDRA                                | Frequency of adverse reactions   |  |
|---|----------------------------------|--|
|   | Very common ( $\geq 1/10$ )      | Common ( $\geq 1/100$ to $< 1/10$ )  |
| <b>Nervous system disorders</b>                             | Headache                         | Dizziness  |
| <b>Gastrointestinal disorders</b>                           | Nausea<br>Lower abdominal pain   | Diarrhoea<br>Vomiting  |
| <b>Reproductive system and breast disorders</b>             | Bleeding not related to menses * | Delay of menses more than 7 days **<br>Irregular menstruation<br>Breast tenderness |
| <b>General disorders and administration site conditions</b> | Fatigue                          |  |

\* Bleeding patterns may be temporarily disturbed, but most women will have their next menstrual period within 5-7 days of the expected time.

\*\* If the next menstrual period is more than 5 days overdue, pregnancy should be excluded.

*From Post-marketing surveillance additionally, the following adverse events have been reported:*

##### *Gastrointestinal disorders*

Very rare ( $<1/10,000$ ): abdominal pain

##### *Skin and subcutaneous tissue disorders*

Very rare ( $<1/10,000$ ): rash, urticaria, pruritus

##### *Reproductive system and breast disorders*

Very rare ( $<1/10,000$ ): pelvic pain, dysmenorrhoea

##### *General disorders and administration site conditions*

Very rare ( $<1/10,000$ ): face oedema

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

#### 4.9 Overdose

Serious undesirable effects have not been reported following acute ingestion of large doses of oral contraceptives. Overdose may cause nausea and withdrawal bleeding may occur. There are no specific antidotes and treatment should be symptomatic.

## 5. PHARMACOLOGICAL PROPERTIES

## 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Sex hormones and modulators of the genital system, emergency contraceptives, ATC code: G03AD01

### Mechanism of action

At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest. Levonorgestrel 1.5 mg is not effective once the process of implantation has begun.

### Clinical efficacy and safety

Results from a randomised, double-blind clinical study conducted in 2001 (Lancet 2002; 360: 1803-1810) showed that a 1500 microgram single dose of levonorgestrel (taken within 72 hours of unprotected sex) prevented 84% of expected pregnancies (compared with 79% when the two 750 microgram tablets were taken 12 hours apart).

There is limited and inconclusive data on the effect of high body weight/high BMI on the contraceptive efficacy. In three WHO studies no trend for a reduced efficacy with increasing body weight/BMI was observed (Table 1), whereas in the two other studies (Creinin et al., 2006 and Glasier et al., 2010) a reduced contraceptive efficacy was observed with increasing body weight or BMI (Table 2). Both meta-analyses excluded intake later than 72 hours after unprotected intercourse (i.e. off-label use of levonorgestrel) and women who had further acts of unprotected intercourse.

Table 1: Meta-analysis on three WHO studies (Von Hertzen et al., 1998 and 2002; Dada et al., 2010)

| <b>BMI (kg/m<sup>2</sup>)</b> | <b>Underweight 0-18.5</b> | <b>Normal 18.5-25</b> | <b>Overweight 25-30</b> | <b>Obese ≥ 30</b> |
|-------------------------------|---------------------------|-----------------------|-------------------------|-------------------|
| <b>N total</b>                | 600                       | 3952                  | 1051                    | 256               |
| <b>N pregnancies</b>          | 11                        | 39                    | 6                       | 3                 |
| <b>Pregnancy rate</b>         | 1.83%                     | 0.99%                 | 0.57%                   | 1.17%             |
| <b>Confidence Interval</b>    | 0.92 - 3.26               | 0.70 – 1.35           | 0.21 – 1.24             | 0.24 – 3.39       |

Table 2: Meta-analysis on studies of Creinin et al., 2006 and Glasier et al., 2010

| <b>BMI (kg/m<sup>2</sup>)</b> | <b>Underweight 0-18.5</b> | <b>Normal 18.5-25</b> | <b>Overweight 25-30</b> | <b>Obese ≥ 30</b> |
|-------------------------------|---------------------------|-----------------------|-------------------------|-------------------|
| <b>N total</b>                | 64                        | 933                   | 339                     | 212               |
| <b>N pregnancies</b>          | 1                         | 9                     | 8                       | 11                |
| <b>Pregnancy rate</b>         | 1.56%                     | 0.96%                 | 2.36%                   | 5.19%             |
| <b>Confidence Interval</b>    | 0.04 – 8.40               | 0.44 – 1.82           | 1.02 – 4.60             | 2.62 – 9.09       |

At the recommended regimen, levonorgestrel is not expected to induce significant modification of blood clotting factors, and lipid and carbohydrate metabolism.

### Paediatric population

A prospective observational study showed that out of 305 treatments with levonorgestrel emergency contraceptive tablets, seven women became pregnant resulting in an overall failure rate of 2.3%. The failure rate in women under 18 years (2.6% or 4/153) was comparable to the failure rate in women 18 years and over (2.0% or 3/152).

## 5.2 Pharmacokinetic properties

### Absorption

Orally administered levonorgestrel is rapidly and almost completely absorbed.

### Distribution

The results of a pharmacokinetic study carried out with 16 healthy women showed that following ingestion of one tablet of levonorgestrel 1.5 mg maximum drug serum levels of levonorgestrel of 18.5 ng/ml were found at 2 hours. After reaching maximum serum levels, the concentration of levonorgestrel decreased with a mean elimination half-life of about 26 hours.

### Biotransformation

Levonorgestrel is not excreted in unchanged form but as metabolites.

### Elimination

Levonorgestrel metabolites are excreted in about equal proportions with urine and faeces. The biotransformation follows the known pathways of steroid metabolism, the levonorgestrel is hydroxylated liver enzymes mainly by CYP3A4 and its metabolites are excreted after glucuronidation by liver glucuronidase enzymes. (See section 4.5).

No pharmacologically active metabolites are known.

Levonorgestrel is bound to serum albumin and sex hormone binding globulin (SHBG). Only about 1.5% of the total serum levels are present as free steroid, but 65% are specifically bound to SHBG.

The absolute bioavailability of levonorgestrel was determined to be almost 100% of the dose administered.

About 0.1% of the maternal dose can be transferred via milk to the nursed infant.

## 5.3 Preclinical safety data

Animal experiments with levonorgestrel have shown virilisation of female foetuses at high doses.

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, carcinogenicity potential beyond the information included in other section of the SmPC.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Lactose monohydrate,  
Maize starch,  
Povidone K25 (E1201),  
Silica, colloidal anhydrous (E551),  
Magnesium stearate (E572)

**6.2 Incompatibilities**

Not applicable

**6.3 Shelf life**

3 years

**6.4 Special precautions for storage**

This medicinal product does not require any special storage conditions

**6.5 Nature and contents of container**

PVC/ PVDC Aluminum-blister containing one tablet. The blister is packed in a carton.

**6.6 Special precautions for disposal and other handling**

A risk of environment impact cannot be excluded for levonorgestrel. Do not throw away any medicines via wastewater <or household waste>. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

**7. MARKETING AUTHORISATION HOLDER:**

Healthypharm B.V.  
Van de Reijtstraat 31-E  
4814 NE Breda  
Nederland

**8. MARKETING AUTHORISATION NUMBER(S)**

RVG 118175

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Datum van eerste verlening van de vergunning: 17 maart 2017  
Datum van laatste verlenging van de vergunning: 25 januari 2022

**10. DATE OF REVISION OF THE TEXT**

Laatste gedeeltelijke wijziging betreft rubriek 9: 3 februari 2023.